Tracy M Frech

List of Publications by Year
in descending order

114 papers	4,034 citations	186265 28 h-index	128289 60 g-index
116 all docs	116 docs citations	116 times ranked	3912 citing authors

#	Article	IF	Citations
1	Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial. Lancet Respiratory Medicine,the, 2016, 4, 708-719.	10.7	754
2	Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial. Lancet, The, 2016, 387, 2630-2640.	13.7	505
3	Safety and efficacy of subcutaneous tocilizumab in systemic sclerosis: results from the open-label period of a phase II randomised controlled trial (faSScinate). Annals of the Rheumatic Diseases, 2018, 77, 212-220.	0.9	236
4	Standardisation of nailfold capillaroscopy for the assessment of patients with Raynaud's phenomenon and systemic sclerosis. Autoimmunity Reviews, 2020, 19, 102458.	5.8	231
5	Immunochip Analysis Identifies Multiple Susceptibility Loci for Systemic Sclerosis. American Journal of Human Genetics, 2014, 94, 47-61.	6.2	182
6	Abatacept in Early Diffuse Cutaneous Systemic Sclerosis: Results of a Phase <scp>II</scp> Investigatorâ€Initiated, Multicenter, Doubleâ€Blind, Randomized, Placeboâ€Controlled Trial. Arthritis and Rheumatology, 2020, 72, 125-136.	5.6	163
7	Survival and Predictors of Mortality in Systemic Sclerosisâ€Associated Pulmonary Arterial Hypertension: Outcomes From the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma Registry. Arthritis Care and Research, 2014, 66, 489-495.	3.4	132
8	Global skin gene expression analysis of early diffuse cutaneous systemic sclerosis shows a prominent innate and adaptive inflammatory profile. Annals of the Rheumatic Diseases, 2020, 79, 379-386.	0.9	97
9	Baseline characteristics and follow-up in patients with normal haemodynamics versus borderline mean pulmonary arterial pressure in systemic sclerosis: results from the PHAROS registry. Annals of the Rheumatic Diseases, 2012, 71, 1335-1342.	0.9	82
10	Long-Term Outcomes in Systemic Sclerosis-Associated Pulmonary Arterial Hypertension From the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma Registry (PHAROS). Chest, 2018, 154, 862-871.	0.8	72
11	Vascular Leaking, a Pivotal and Early Pathogenetic Event in Systemic Sclerosis: Should the Door Be Closed?. Frontiers in Immunology, 2018, 9, 2045.	4.8	67
12	Safety and Efficacy of Lenabasum in a Phase II, Randomized, Placeboâ€Controlled Trial in Adults With Systemic Sclerosis. Arthritis and Rheumatology, 2020, 72, 1350-1360.	5.6	67
13	Antinuclear antibody-negative systemic sclerosis. Seminars in Arthritis and Rheumatism, 2015, 44, 680-686.	3.4	60
14	Multinational Qualitative Research Study Exploring the Patient Experience of Raynaud's Phenomenon in Systemic Sclerosis. Arthritis Care and Research, 2018, 70, 1373-1384.	3.4	54
15	The Scleroderma Patient-Centered Intervention Network Cohort: baseline clinical features and comparison with other large scleroderma cohorts. Rheumatology, 2018, 57, 1623-1631.	1.9	53
16	Prevalence and correlates of sleep disturbance in systemic sclerosis--results from the UCLA scleroderma quality of life study. Rheumatology, 2011, 50, 1280-1287.	1.9	48
17	Probiotics for the treatment of systemic sclerosis-associated gastrointestinal bloating/ distention. Clinical and Experimental Rheumatology, 2011, 29, S22-5.	0.8	46
18	Heritability of vasculopathy, autoimmune disease, and fibrosis in systemic sclerosis: A populationâ€based study. Arthritis and Rheumatism, 2010, 62, 2109-2116.	6.7	42

#	Article	IF	Citations
19	Generation of a Core Set of Items to Develop Classification Criteria for Scleroderma Renal Crisis Using Consensus Methodology. Arthritis and Rheumatology, 2019, 71, 964-971.	5.6	41
20	Gastrointestinal and Hepatic Disease in Systemic Sclerosis. Rheumatic Disease Clinics of North America, 2018, 44, 15-28.	1.9	39
21	Vascular Leak Is a Central Feature in the Pathogenesis of Systemic Sclerosis. Journal of Rheumatology, 2012, 39, 1385-1391.	2.0	36
22	Performance Characteristics of Pulmonary Function Tests for the Detection of Interstitial Lung Disease in Adults With Early Diffuse Cutaneous Systemic Sclerosis. Arthritis and Rheumatology, 2020, 72, 1892-1896.	5.6	36
23	Safety and efficacy of abatacept in early diffuse cutaneous systemic sclerosis (ASSET): open-label extension of a phase 2, double-blind randomised trial. Lancet Rheumatology, The, 2020, 2, e743-e753.	3.9	34
24	Systemic sclerosis induces pronounced peripheral vascular dysfunction characterized by blunted peripheral vasoreactivity and endothelial dysfunction. Clinical Rheumatology, 2015, 34, 905-913.	2.2	33
25	Patient-reported outcome instruments for assessing Raynaudâ€™s phenomenon in systemic sclerosis: A SCTC vascular working group report. Journal of Scleroderma and Related Disorders, 2018, 3, 249-252.	1.7	33
26	Validation of the Selfâ€Efficacy for Managing Chronic Disease Scale: A Scleroderma Patientâ€Centered Intervention Network Cohort Study. Arthritis Care and Research, 2016, 68, 1195-1200.	3.4	31
27	Clinical characteristics, visceral involvement, and mortality in at-risk or early diffuse systemic sclerosis: a longitudinal analysis of an observational prospective multicenter US cohort. Arthritis Research and Therapy, 2021, 23, 170.	3.5	30
28	Treatment of early diffuse systemic sclerosis skin disease. Clinical and Experimental Rheumatology, 2013, 31, 166-71.	0.8	30
29	The Critical Need for Accurately Defining Digital Ulcers in Scleroderma. Journal of Scleroderma and Related Disorders, 2017, 2, 69-71.	1.7	29
30	The utility of nutraceuticals in the treatment of osteoarthritis. Current Rheumatology Reports, 2007, 9, 25-30.	4.7	28
31	Low-Dose Naltrexone for Pruritus in Systemic Sclerosis. International Journal of Rheumatology, 2011, 2011, 1-5.	1.6	28
32	Nutritional status and gastrointestinal symptoms in systemic sclerosis patients. Clinical Nutrition, 2013, 32, 130-135.	5.0	27
33	Automated Measurement of Microvascular Function Reveals Dysfunction in Systemic Sclerosis: A Cross-sectional Study. Journal of Rheumatology, 2017, 44, 1603-1611.	2.0	26
34	Digital Ulcers in Ssc Treated with Oral Treprostinil: A Randomized, Double-Blind, Placebo-Controlled Study with Open-Label Follow-up. Journal of Scleroderma and Related Disorders, 2017, 2, 42-49.	1.7	25
35	Multicenter Qualitative Study Exploring the Patient Experience of Digital Ulcers in Systemic Sclerosis. Arthritis Care and Research, 2020, 72, 723-733.	3.4	25
36	Changes in mental health symptoms from pre-COVID-19 to COVID-19 among participants with systemic sclerosis from four countries: A Scleroderma Patient-centered Intervention Network (SPIN) Cohort study. Journal of Psychosomatic Research, 2020, 139, 110262.	2.6	25

#	Article	IF	Citations
37	Factors Influencing Raynaud Condition Score Diary Outcomes in Systemic Sclerosis. Journal of Rheumatology, 2019, 46, 1326-1334.	2.0	24
38	Evolving Symptom Characteristics of Raynaud's Phenomenon in Systemic Sclerosis and Their Association With Physician and Patientâ€Reported Assessments of Disease Severity. Arthritis Care and Research, 2019, 71, 1119-1126.	3.4	23
39	A comprehensive framework for navigating patient care in systemic sclerosis: A global response to the need for improving the practice of diagnostic and preventive strategies in SSc. Best Practice and Research in Clinical Rheumatology, 2021, 35, 101707.	3.3	22
40	A multicenter randomized, double-blind, placebo-controlled pilot study to assess the efficacy and safety of riociguat in systemic sclerosis-associated digital ulcers. Arthritis Research and Therapy, 2019, 21, 202.	3.5	21
41	Predictive Significance of Serum Interferonâ€Inducible Protein Score for Response to Treatment in Systemic Sclerosisâ€"Related Interstitial Lung Disease. Arthritis and Rheumatology, 2021, 73, 1005-1013.	5.6	21
42	Protocol for a partially nested randomised controlled trial to evaluate the effectiveness of the scleroderma patient-centered intervention network COVID-19 home-isolation activities together (SPIN-CHAT) program to reduce anxiety among at-risk scleroderma patients. Journal of Psychosomatic Research, 2020, 135, 110132.	2.6	21
43	Reporting items for capillaroscopy in clinical research on musculoskeletal diseases: a systematic review and international Delphi consensus. Rheumatology, 2021, 60, 1410-1418.	1.9	20
44	Exercise as a multi-modal disease-modifying medicine in systemic sclerosis: An introduction by The Global Fellowship on Rehabilitation and Exercise in Systemic Sclerosis (G-FoRSS). Best Practice and Research in Clinical Rheumatology, 2021, 35, 101695.	3.3	19
45	Genetic susceptibility loci of idiopathic interstitial pneumonia do not represent risk for systemic sclerosis: a case control study in Caucasian patients. Arthritis Research and Therapy, 2016, 18, 20.	3.5	18
46	Peripheral neuropathy: a complication of systemic sclerosis. Clinical Rheumatology, 2013, 32, 885-888.	2.2	17
47	Autophagy is a key feature in the pathogenesis of systemic sclerosis. Rheumatology International, 2014, 34, 435-439.	3.0	17
48	The Recurrence of Digital Ulcers in Patients with Systemic Sclerosis after Discontinuation of Oral Treprostinil. Journal of Rheumatology, 2016, 43, 1665-1671.	2.0	17
49	Review of local wound management for scleroderma-associated digital ulcers. Journal of Scleroderma and Related Disorders, 2018, 3, 66-70.	1.7	17
50	Primary care assessment of capillaroscopy abnormalities in patients with Raynaudâ€™s phenomenon. Clinical Rheumatology, 2015, 34, 2135-2140.	2.2	16
51	Reliability and Validity of the Tender and Swollen Joint Counts and the Modified Rodnan Skin Score in Early Diffuse Cutaneous Systemic Sclerosis: Analysis from the Prospective Registry of Early Systemic Sclerosis Cohort. Journal of Rheumatology, 2017, 44, 791-794.	2.0	14
52	Patient acceptable symptom state in scleroderma: results from the tocilizumab compared with placebo trial in active diffuse cutaneous systemic sclerosis. Rheumatology, 2018, 57, 152-157.	1.9	13
53	An interim report of the Scleroderma Clinical Trials Consortium working groups. Journal of Scleroderma and Related Disorders, 2019, 4, 17-27.	1.7	13
54	Longitudinal Assessment of Patient-reported Outcome Measures in Systemic Sclerosis Patients with Gastroesophageal Reflux Disease â€" Scleroderma Clinical Trials Consortium. Journal of Rheumatology, 2019, 46, 78-84.	2.0	13

#	Article	IF	Citations
55	Identifying barriers and facilitators to physical activity for people with scleroderma: a nominal group technique study. Disability and Rehabilitation, 2021, 43, 3339-3346.	1.8	12
56	The Prevalence and Clinical Correlates of an Auscultatory Gap in Systemic Sclerosis Patients. International Journal of Rheumatology, 2012, 2012, 1-4.	1.6	11
57	Exercise-induced brachial artery blood flow and vascular function is impaired in systemic sclerosis. American Journal of Physiology - Heart and Circulatory Physiology, 2016, 311, H1375-H1381.	3.2	11
58	Patient experiences of digital ulcer development and evolution in systemic sclerosis. Rheumatology, 2020, 59, 2156-2158.	1.9	11
59	Informatics can identify systemic sclerosis (SSc) patients at risk for scleroderma renal crisis. Computers in Biology and Medicine, 2014, 53, 203-205.	7.0	10
60	Sublingual Abnormalities in Systemic Sclerosis. Journal of Clinical Rheumatology, 2016, 22, 19-21.	0.9	10
61	Systemic sclerosis: The need for structured care. Best Practice and Research in Clinical Rheumatology, 2016, 30, 3-21.	3.3	10
62	Factors associated with fears due to COVID-19: A Scleroderma Patient-centered Intervention Network (SPIN) COVID-19 cohort study. Journal of Psychosomatic Research, 2021, 140, 110314.	2.6	9
63	Pain levels and associated factors in the Scleroderma Patient-centered Intervention Network (SPIN) cohort: a multicentre cross-sectional study. Lancet Rheumatology, The, 2021, 3, e844-e854.	3.9	9
64	Expanding Personalized, Data-Driven Dermatology: Leveraging Digital Health Technology and Machine Learning to Improve Patient Outcomes. JID Innovations, 2022, 2, 100105.	2.4	9
65	Reliability and Validity of Three Versions of the Brief Fear of Negative Evaluation Scale in Patients With Systemic Sclerosis: A Scleroderma Patientâ€Centered Intervention Network Cohort Study. Arthritis Care and Research, 2018, 70, 1646-1652.	3.4	8
66	Collaborative National Quality and Efficacy Registry (CONQUER) for Scleroderma: outcomes from a multicenter US-based systemic sclerosis registry. Clinical Rheumatology, 2020, 39, 93-102.	2.2	8
67	Protective role of interleukin-6 in systemic sclerosis gastrointestinal tract involvement: case report and review of the literature. Clinical and Experimental Rheumatology, 2015, 33, S179-81.	0.8	8
68	The Vascular Microenvironment and Systemic Sclerosis. International Journal of Rheumatology, 2010, 2010, 1-6.	1.6	7
69	Cardiac metabolomics and autopsy in a patient with early diffuse systemic sclerosis presenting with dyspnea: a case report. Journal of Medical Case Reports, 2015, 9, 136.	0.8	7
70	Does hand involvement in systemic sclerosis limit completion of patient-reported outcome measures?. Clinical Rheumatology, 2021, 40, 965-971.	2.2	7
71	The Scleroderma Patient-Centered Intervention Network Self-Management Program: Protocol for a Randomized Feasibility Trial. JMIR Research Protocols, 2020, 9, e16799.	1.0	7
72	Patient participation in patient-reported outcome instrument development in systemic sclerosis. Clinical and Experimental Rheumatology, 2017, 35 Suppl 106, 184-192.	0.8	7

#	Article	IF	Citations
73	Acute oral tetrahydrobiopterin administration ameliorates endothelial dysfunction in systemic sclerosis. Clinical and Experimental Rheumatology, 2017, 35 Suppl 106, 167-172.	0.8	6
74	Understanding itch in systemic sclerosis in order to improve patient quality of life. Clinical and Experimental Rheumatology, 2013, 31, 81-8.	0.8	6
75	Does sublingual microscopy correlate with nailfold videocapillaroscopy in systemic sclerosis?. Clinical Rheumatology, 2021, 40, 2263-2266.	2.2	5
76	Non-invasive digital thermal monitoring and flow-mediated dilation in systemic sclerosis. Clinical and Experimental Rheumatology, 2019, 37 Suppl 119, 97-101.	0.8	5
77	A novel transition clinic structure for adolescent and young adult patients with childhood onset rheumatic disease improves transition outcomes. Pediatric Rheumatology, 2021, 19, 164.	2.1	5
78	Results from an American pilot survey among Scleroderma Clinical Trials Consortium members on capillaroscopy use and how to best implement nailfold capillaroscopy training. Clinical and Experimental Rheumatology, 2019, 37 Suppl 119, 151.	0.8	5
79	Attenuated nitric oxide bioavailability in systemic sclerosis: Evidence from the novel assessment of passive leg movement. Experimental Physiology, 2018, 103, 1412-1424.	2.0	4
80	Presence of Antitopoisomerase I Antibody Alone May Not Be Sufficient for the Diagnosis of Systemic Sclerosis. Journal of Rheumatology, 2019, 46, 440-442.	2.0	4
81	Small intestinal bacterial overgrowth in systemic sclerosis. Journal of Scleroderma and Related Disorders, 2020, 5, 33-39.	1.7	4
82	Barriers and Facilitators to Physical Activity for People With Scleroderma: A Scleroderma Patientâ€Centered Intervention Network Cohort Study. Arthritis Care and Research, 2022, 74, 1300-1310.	3.4	4
83	The Scleroderma Patient-centered Intervention Network Self-Management (SPIN-SELF) Program: protocol for a two-arm parallel partially nested randomized controlled feasibility trial with progression to full-scale trial. Trials, 2021, 22, 856.	1.6	4
84	Validation of the Body Concealment Scale for Scleroderma (BCSS): Replication in the Scleroderma Patient-centered Intervention Network (SPIN) Cohort. Body Image, 2017, 20, 99-106.	4.3	3
85	Understanding empirical therapeutics in systemic sclerosis gastrointestinal tract disease. Rheumatology, 2017, 56, 176-177.	1.9	3
86	Gut Disease in Systemic Sclerosisâ€"New Approaches to Common Problems. Current Treatment Options in Rheumatology, 2019, 5, 11-19.	1.4	3
87	A double-blind, placebo-controlled, phase II, randomized study of lovastatin therapy in the treatment of mildly active rheumatoid arthritis. Rheumatology, 2020, 59, 1505-1513.	1.9	3
88	Big data in systemic sclerosis: Great potential for the future. Journal of Scleroderma and Related Disorders, 2020, 5, 172-177.	1.7	3
89	Effect of Coping Strategies on Patient and Physician Perceptions of Disease Severity and Disability in Systemic Sclerosis. Journal of Rheumatology, 2021, 48, 1569-1573.	2.0	3
90	Implications of endothelial shear stress on systemic sclerosis vasculopathy and treatment. Clinical and Experimental Rheumatology, 2018, 36 Suppl 113, 175-182.	0.8	3

#	Article	IF	Citations
91	Baseline characteristics of systemic sclerosis patients with restrictive lung disease in a multiâ€center USâ€based longitudinal registry. International Journal of Rheumatic Diseases, 2022, 25, 163-174.	1.9	3
92	Randomized feasibility trial of the Scleroderma Patient-centered Intervention Network Self-Management (SPIN-SELF) Program. Pilot and Feasibility Studies, 2022, 8, 45.	1.2	3
93	Parental Influence on Systemic Sclerosis. Arthritis Care and Research, 2015, 67, 310-312.	3.4	2
94	Eosinophilic Esophagitis in Two Patients with Systemic Sclerosis. Case Reports in Rheumatology, 2016, 2016, 1-5.	0.6	2
95	A normal diffusing capacity of the lungs for carbon monoxide is rare in incidental pulmonary arterial hypertension in systemic sclerosis: Data from the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma cohort. Journal of Scleroderma and Related Disorders, 2018, 3, 237-241.	1.7	2
96	Raynaud Phenomenon in Systemic Sclerosis: Does Digital Thermal Monitoring Correlate to Specific Nailfold Videocapillaroscopy Abnormalities?. Journal of Rheumatology, 2021, 48, 247-250.	2.0	2
97	The frequency of Raynaudâ€™s phenomenon, very early diagnosis of systemic sclerosis, and systemic sclerosis in a large Veteran Health Administration database. BMC Rheumatology, 2021, 5, 42.	1.6	2
98	Treatment of ankylosing spondylitis: focus on etanercept. Biologics: Targets and Therapy, 2007, 1, 45-51.	3.2	2
99	Chronic Multiorgan Rare Disease: The Role of the Nurse Practitioner as a Leader of the Healthcare Team. Journal of Medical Practice Management, 2017, 32, 413-416.	0.1	2
100	Tetrahydrobiopterin Administration Augments Exercise-Induced Hyperemia and Endothelial Function in Patients With Systemic Sclerosis. Frontiers in Medicine, 2021, 8, 791689.	2.6	2
101	Computed Tomography of the Chest to Screen for Interstitial Lung Disease in Patients With Systemic Sclerosis at Expert Scleroderma Centers in the United States. ACR Open Rheumatology, 2022, 4, 596-602.	2.1	2
102	Bone Mineral Density in Navajo Men and Women and Comparison to Non-Hispanic Whites from NHANES (2005â€“2008). Journal of Health Care for the Poor and Underserved, 2016, 27, 644-662.	0.8	1
103	Treatment efficacy in secondary Raynaud's phenomenon. Lancet Rheumatology, The, 2020, 2, e132.	3.9	1
104	Pulmonary Vascular Resistance in Systemic Sclerosis Patients With Pulmonary Hypertension. Chest, 2011, 140, 717A.	0.8	0
105	Implementation of an advance directive focus in a Chronic Multi-Organ Rare Disease Clinic. Annals of Palliative Medicine, 2017, 6, S206-S208.	1.2	0
106	i068â€ƒThe evaluation and management of gastrointestinal manifestations of systemic sclerosis. Rheumatology, 2018, 57, .	1.9	0
107	Pauling and Frech reply. Journal of Rheumatology, 2019, 46, 1544-1545.	2.0	0
108	Dr. Tebo, et al, reply. Journal of Rheumatology, 2019, 46, 1547.2-1547.	2.0	0

#	Article	IF	Citations
109	Reply. Arthritis and Rheumatology, 2021, 73, 716-717.	5.6	0
110	Clinical Bedside Tools to Assess Systemic Sclerosis Vasculopathy: Can Digital Thermal Monitoring and Sublingual Microscopy Identify Patients With Digital Ulcers?. Journal of Rheumatology, 2021, 48, 1566-1568.	2.0	0
111	Routine Chest Radiographs Are Not Necessary Following Ultrasound Guided Right Heart Catheterization. Chest, 2011, 140, 718A.	0.8	0
112	The Impact of Acute Tetrahydrobiopterin Administration on Plasma Adropin Concentration in Patients with Systemic Sclerosis. FASEB Journal, 2018, 32, 902.20.	0.5	0
113	Oesophageal disease in systemic sclerosis: does heritability play a role?. Clinical and Experimental Rheumatology, 2017, 35 Suppl 106, 86-88.	0.8	0
114	Is it Still â€˜Idiopathicâ€™?: Features of Autoimmunity in IPAH. American Journal of Respiratory and Critical Care Medicine, 2022, , .	5.6	0